phenobarbital has been researched along with Drug Refractory Epilepsy in 10 studies
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This model consists in inducing daily generalized seizures for 23 consecutive days by administration of 3-mercaptopropionic acid (MP)." | 7.85 | New model of pharmacoresistant seizures induced by 3-mercaptopropionic acid in mice. ( Bruno Blanch, L; Castaño, R; Enrique, A; Girardi, E; Goicoechea, S; Orozco, S; Rocha, L; Taborda, F, 2017) |
| "Background Phenobarbital is the first-line choice for neonatal seizures treatment, despite a response rate of approximately 45%." | 7.83 | Phenobarbital for Neonatal Seizures: Response Rate and Predictors of Refractoriness. ( Mazzotta, S; Pavlidis, E; Pelosi, A; Pisani, F; Seri, S; Spagnoli, C, 2016) |
| "To evaluate the efficacy and safety of mega-dose phenobarbital (MDPB; enteral or parenteral phenobarbital >10 mg/kg/day) for treating super-refractory status epilepticus (SRSE; continuous or recurrent status epilepticus for ≥24 hours after the onset of continuous anaesthetic treatment) in adult patients." | 7.81 | Mega-dose phenobarbital therapy for super-refractory status epilepticus. ( Byun, JI; Chu, K; Jeon, D; Jun, JS; Jung, KH; Jung, KY; Kim, TJ; Lee, DY; Lee, HS; Lee, SK; Lee, ST; Lee, WJ; Lim, JA; Moon, J; Sunwoo, JS, 2015) |
| " In pentylenetetrazole-induced acute seizures only BUM532 combined with a sub-effective dose of PB increased the seizure threshold." | 3.96 | Functional characterization of novel bumetanide derivatives for epilepsy treatment. ( Auer, T; Erker, T; Schreppel, P; Schwarzer, C, 2020) |
| " This model consists in inducing daily generalized seizures for 23 consecutive days by administration of 3-mercaptopropionic acid (MP)." | 3.85 | New model of pharmacoresistant seizures induced by 3-mercaptopropionic acid in mice. ( Bruno Blanch, L; Castaño, R; Enrique, A; Girardi, E; Goicoechea, S; Orozco, S; Rocha, L; Taborda, F, 2017) |
| "Background Phenobarbital is the first-line choice for neonatal seizures treatment, despite a response rate of approximately 45%." | 3.83 | Phenobarbital for Neonatal Seizures: Response Rate and Predictors of Refractoriness. ( Mazzotta, S; Pavlidis, E; Pelosi, A; Pisani, F; Seri, S; Spagnoli, C, 2016) |
| "To evaluate the efficacy and safety of mega-dose phenobarbital (MDPB; enteral or parenteral phenobarbital >10 mg/kg/day) for treating super-refractory status epilepticus (SRSE; continuous or recurrent status epilepticus for ≥24 hours after the onset of continuous anaesthetic treatment) in adult patients." | 3.81 | Mega-dose phenobarbital therapy for super-refractory status epilepticus. ( Byun, JI; Chu, K; Jeon, D; Jun, JS; Jung, KH; Jung, KY; Kim, TJ; Lee, DY; Lee, HS; Lee, SK; Lee, ST; Lee, WJ; Lim, JA; Moon, J; Sunwoo, JS, 2015) |
| "To identify factors associated with low benzodiazepine (BZD) dosing in patients with refractory status epilepticus (RSE) and to assess the impact of BZD treatment variability on seizure cessation." | 1.56 | First-line medication dosing in pediatric refractory status epilepticus. ( Abend, NS; Amengual-Gual, M; Anderson, A; Arya, R; Brenton, JN; Carpenter, JL; Chapman, K; Clark, J; Farias-Moeller, R; Gaillard, WD; Gaínza-Lein, M; Glauser, T; Goldstein, JL; Goodkin, HP; Guerriero, RM; Kapur, K; Lai, YC; Loddenkemper, T; McDonough, TL; Mikati, MA; Morgan, LA; Novotny, EJ; Ostendorf, AP; Payne, ET; Peariso, K; Piantino, J; Riviello, JJ; Sannagowdara, K; Tasker, RC; Tchapyjnikov, D; Topjian, A; Vasquez, A; Wainwright, MS; Wilfong, A; Williams, K, 2020) |
| "Status epilepticus is defined as a state of unrelenting seizure activity." | 1.51 | Excitatory GABAergic signalling is associated with benzodiazepine resistance in status epilepticus. ( Akerman, CJ; Burman, RJ; Calin, A; Codadu, NK; Katz, AA; Lee, JH; Newey, SE; Parrish, RR; Raimondo, JV; Selfe, JS; Trevelyan, AJ; van den Berg, M; Wilmshurst, JM; Wright, R, 2019) |
| "Perampanel (PER) is a new antiepileptic drug (AED) with a novel mechanism of action." | 1.51 | Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy. ( Ishikawa, N; Kobayashi, M; Kobayashi, Y; Tani, H; Tateishi, Y, 2019) |
| "Lamotrigine and valproate were rated most successful with good or partial response rates in 88-100% of the patients." | 1.43 | LIS1-associated classic lissencephaly: A retrospective, multicenter survey of the epileptogenic phenotype and response to antiepileptic drugs. ( Beaud, N; Borggraefe, I; Budde, J; Debus, O; Ensslen, M; Geis, T; Gilbert, M; Haeussler, M; Hahn, A; Hehr, U; Heiming, R; Herbst, SM; Kurlemann, G; Morgner, R; Morris-Rosendahl, DJ; Muelleder, K; Philippi, H; Proepper, CR; Ross, S; Schuierer, G; Strobl-Wildemann, G; von Gersdorff, G; Vosschulte, P, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Auer, T | 1 |
| Schreppel, P | 1 |
| Erker, T | 1 |
| Schwarzer, C | 1 |
| Burman, RJ | 1 |
| Selfe, JS | 1 |
| Lee, JH | 1 |
| van den Berg, M | 1 |
| Calin, A | 1 |
| Codadu, NK | 1 |
| Wright, R | 1 |
| Newey, SE | 1 |
| Parrish, RR | 1 |
| Katz, AA | 1 |
| Wilmshurst, JM | 1 |
| Akerman, CJ | 1 |
| Trevelyan, AJ | 1 |
| Raimondo, JV | 1 |
| Koneval, Z | 1 |
| Knox, KM | 1 |
| Memon, A | 1 |
| Zierath, DK | 1 |
| White, HS | 1 |
| Barker-Haliski, M | 1 |
| Vasquez, A | 1 |
| Gaínza-Lein, M | 1 |
| Abend, NS | 1 |
| Amengual-Gual, M | 1 |
| Anderson, A | 1 |
| Arya, R | 1 |
| Brenton, JN | 1 |
| Carpenter, JL | 1 |
| Chapman, K | 1 |
| Clark, J | 1 |
| Farias-Moeller, R | 1 |
| Gaillard, WD | 1 |
| Glauser, T | 1 |
| Goldstein, JL | 1 |
| Goodkin, HP | 1 |
| Guerriero, RM | 1 |
| Kapur, K | 1 |
| Lai, YC | 1 |
| McDonough, TL | 1 |
| Mikati, MA | 1 |
| Morgan, LA | 1 |
| Novotny, EJ | 1 |
| Ostendorf, AP | 1 |
| Payne, ET | 1 |
| Peariso, K | 1 |
| Piantino, J | 1 |
| Riviello, JJ | 1 |
| Sannagowdara, K | 1 |
| Tasker, RC | 1 |
| Tchapyjnikov, D | 1 |
| Topjian, A | 1 |
| Wainwright, MS | 1 |
| Wilfong, A | 1 |
| Williams, K | 1 |
| Loddenkemper, T | 1 |
| Ishikawa, N | 1 |
| Tateishi, Y | 1 |
| Tani, H | 1 |
| Kobayashi, Y | 1 |
| Kobayashi, M | 1 |
| Herbst, SM | 1 |
| Proepper, CR | 1 |
| Geis, T | 1 |
| Borggraefe, I | 1 |
| Hahn, A | 1 |
| Debus, O | 1 |
| Haeussler, M | 1 |
| von Gersdorff, G | 1 |
| Kurlemann, G | 1 |
| Ensslen, M | 1 |
| Beaud, N | 1 |
| Budde, J | 1 |
| Gilbert, M | 1 |
| Heiming, R | 1 |
| Morgner, R | 1 |
| Philippi, H | 1 |
| Ross, S | 1 |
| Strobl-Wildemann, G | 1 |
| Muelleder, K | 1 |
| Vosschulte, P | 1 |
| Morris-Rosendahl, DJ | 1 |
| Schuierer, G | 1 |
| Hehr, U | 1 |
| Byun, JI | 1 |
| Chu, K | 1 |
| Sunwoo, JS | 1 |
| Moon, J | 1 |
| Kim, TJ | 1 |
| Lim, JA | 1 |
| Jun, JS | 1 |
| Lee, HS | 1 |
| Lee, WJ | 1 |
| Lee, DY | 1 |
| Jeon, D | 1 |
| Lee, ST | 1 |
| Jung, KH | 1 |
| Jung, KY | 1 |
| Lee, SK | 1 |
| Spagnoli, C | 1 |
| Seri, S | 1 |
| Pavlidis, E | 1 |
| Mazzotta, S | 1 |
| Pelosi, A | 1 |
| Pisani, F | 1 |
| Haenisch, S | 1 |
| von Rüden, EL | 1 |
| Wahmkow, H | 1 |
| Rettenbeck, ML | 1 |
| Michler, C | 1 |
| Russmann, V | 1 |
| Bruckmueller, H | 1 |
| Waetzig, V | 1 |
| Cascorbi, I | 1 |
| Potschka, H | 1 |
| Enrique, A | 1 |
| Goicoechea, S | 1 |
| Castaño, R | 1 |
| Taborda, F | 1 |
| Rocha, L | 1 |
| Orozco, S | 1 |
| Girardi, E | 1 |
| Bruno Blanch, L | 1 |
10 other studies available for phenobarbital and Drug Refractory Epilepsy
| Article | Year |
|---|---|
Functional characterization of novel bumetanide derivatives for epilepsy treatment.
Topics: Animals; Anticonvulsants; Blood-Brain Barrier; Brain; Bumetanide; Convulsants; Disease Models, Anima | 2020 |
Excitatory GABAergic signalling is associated with benzodiazepine resistance in status epilepticus.
Topics: Animals; Anticonvulsants; Benzodiazepines; Child, Preschool; Diazepam; Drug Resistance; Drug Resista | 2019 |
Antiseizure drug efficacy and tolerability in established and novel drug discovery seizure models in outbred vs inbred mice.
Topics: Animals; Animals, Outbred Strains; Anticonvulsants; Behavior, Animal; Brain; Carbamazepine; Cornea; | 2020 |
First-line medication dosing in pediatric refractory status epilepticus.
Topics: Adolescent; Age Factors; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Dose-Response Re | 2020 |
Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Dizziness; Drug Resistant Epile | 2019 |
LIS1-associated classic lissencephaly: A retrospective, multicenter survey of the epileptogenic phenotype and response to antiepileptic drugs.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adolescent; Adult; Anticonvulsants; Brain; Child; Ch | 2016 |
Mega-dose phenobarbital therapy for super-refractory status epilepticus.
Topics: Adolescent; Adult; Anticonvulsants; Drug Resistant Epilepsy; Female; Humans; Intensive Care Units; M | 2015 |
Phenobarbital for Neonatal Seizures: Response Rate and Predictors of Refractoriness.
Topics: Anticonvulsants; Drug Resistant Epilepsy; Electroencephalography; Female; Humans; Infant, Newborn; I | 2016 |
miRNA-187-3p-Mediated Regulation of the KCNK10/TREK-2 Potassium Channel in a Rat Epilepsy Model.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Drug Resistant Epilepsy; Dyrk Kinases; Electric St | 2016 |
New model of pharmacoresistant seizures induced by 3-mercaptopropionic acid in mice.
Topics: 3-Mercaptopropionic Acid; Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, M | 2017 |